SCHEMBL2956440

SCHEMBL2956440

CC(C)C1CC(=O)NC1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K14 Q99558 1/20 0.44
CRBN Q96SW2 2/20 0.42
GLA P06280 1/20 0.37
CYP19A1 P11511 1/20 0.34
RAB9A P51151 2/20 0.34
TDP1 Q9NUW8 2/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPT P10636 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
TOP2A P11388 1/20 0.33
TOP2B Q02880 1/20 0.33
APEX1 P27695 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
GAA P10253 1/20 0.33
TSHR P16473 1/20 0.33
DDB1 Q16531 1/20 0.32
NPC1 O15118 1/20 0.32
POLB P06746 1/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25905222 1.00 MAP3K14 (0.44) MAP3K14CRBNGLACYP19A1RAB9A
SCHEMBL25905221 1.00 MAP3K14 (0.44) MAP3K14CRBNGLACYP19A1RAB9A
SCHEMBL1536268 0.82 MAP3K14 (0.41) MAP3K14CRBNGLACYP19A1RAB9A
SCHEMBL22394492 0.82 MAP3K14 (0.41) MAP3K14CRBNGLACYP19A1RAB9A
Ammonia Solution, Strong SCHEMBL27873510 0.80 MAP3K14 (0.40) MAP3K14CRBNGLACYP19A1RAB9A
SCHEMBL26177784 0.79 CRBN (0.41) MAP3K14CRBNRAB9ATDP1ALDH1A1
SCHEMBL755754 0.79 MAP3K14 (0.39) MAP3K14CRBNGLACYP19A1RAB9A
SCHEMBL25467405 0.77 CRBN (0.30) CRBN
SCHEMBL22623767 0.77 CRBN (0.44) CRBNTDP1ALDH1A1TSHRDDB1
SCHEMBL25046231 0.77 CRBN (0.44) CRBNTDP1ALDH1A1TSHRDDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6187083-B1 INK COMPOSITION COMPRISING SELECTED INK VEHICLE, AMIDE VISCOSITY MODIFIER, CONDUCTIVE SULFONATE SALT ALL HAVING MELTING POINTS WITHIN SPECIFIED RANGE, COLORANT, OPTIONAL ANTIOXIDANT AND ULTRAVIOLET ABSORBER XEROX CORPORATION 2001-02-13 US claimed
CN-119421882-A FGFR2 inhibitor compounds 伊莱利利公司 2025-02-11 CN disclosed
WO-2024147972-A2 DNA POLYMERASE THETA INHIBITORS CONTAINING NON-SATURATED 5-MEMBERED HETEROCYCLIC RINGS AND USE THEREOF THOMAS JEFFERSON UNIVERSITY (US) 2024-07-11 WO disclosed
WO-2024052333-A1 MULTIVALENT FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS PHILOCHEM AG (CH) 2024-03-14 WO disclosed
US-20240066138-A1 ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS SHANGHAI RUOTUO BIOSCIENCES CO LTD (CN) 2024-02-29 US disclosed
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-18 US disclosed
US-11834417-B2 Compositions for the treatment of hypertension and/or fibrosis VECTUS BIOSYSTEMS LIMITED (AU) 2023-12-05 US disclosed
US-11834417-B2 Compositions for the treatment of hypertension and/or fibrosis VECTUS BIOSYSTEMS LIMITED (AU) 2023-12-05 US disclosed
US-20230330248-A1 ANTIBODY-DRUG CONJUGATE INCLUDING NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-10-19 US disclosed
US-20230234950-A1 CRBN LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-27 US disclosed
US-20070249770-A1 Binder Resin Composition, Paste and Green Sheet SEKISUI CHEMICAL CO., LTD. (JP) 2007-10-25 US disclosed
US-20070244096-A1 Fused Bicyclic Nitrogen-Containing Heterocycles JAPAN TOBACCO INC. (JP) 2007-10-18 US disclosed
CN-100338139-C Heat-decaying material, transfer sheet using same, and method for forming pattern SEKISUI CHEMICAL CO LTD (JP) 2007-09-19 CN disclosed
US-7265150-B1 Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders GPI NIL HOLDINGS INC. (US) 2007-09-04 US disclosed
US-20070185098-A1 Inhibitors of protein kinases LOCUS PHARMACEUTICALS, INC. (US) 2007-08-09 US disclosed
US-7244727-B2 Fused bicyclic nitrogen-containing heterocycles JAPAN TOBACCO INC. (JP) 2007-07-17 US disclosed
CN-1972995-A Binder resin composition, paste, and green sheet SEKISUI CHEMICAL CO LTD (JP) 2007-05-30 CN disclosed
CN-1708555-A Heat-decaying material, transfer sheet using same, and method for forming pattern SEKISUI CHEMICAL CO LTD (JP) 2005-12-14 CN disclosed
CN-1524104-A Photoreactive composition ��Ԩ��ѧ��ҵ��ʽ���� 2004-08-25 CN disclosed
US-6187083-B1 INK COMPOSITION COMPRISING SELECTED INK VEHICLE, AMIDE VISCOSITY MODIFIER, CONDUCTIVE SULFONATE SALT ALL HAVING MELTING POINTS WITHIN SPECIFIED RANGE, COLORANT, OPTIONAL ANTIOXIDANT AND ULTRAVIOLET ABSORBER XEROX CORPORATION 2001-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234950-A1 CRBN LIGANDS AND USES THEREOF CRBN, CRKL, ERBB3 MAP3K14 1475/4885CRBN 1/4885GLA 3961/4885
US-20230330248-A1 ANTIBODY-DRUG CONJUGATE INCLUDING NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE STING1, CGAS, TLR9 MAP3K14 1842/4885CRBN 714/4885GLA 2707/4885
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF STAT4, STAT1, STAT3 MAP3K14 1416/4885CRBN 171/4885GLA 1055/4885
US-20070244096-A1 Fused Bicyclic Nitrogen-Containing Heterocycles PC, HCCS, MYC MAP3K14 1686/4885CRBN 719/4885GLA 2574/4885
US-11834417-B2 Compositions for the treatment of hypertension and/or fibrosis TGFB1, REN, TGFB2 MAP3K14 1319/4885CRBN 3368/4885GLA 1068/4885
US-20240066138-A1 ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS FCGR1A, FCGRT, FCGR2A MAP3K14 2551/4885CRBN 822/4885GLA 727/4885
US-20070185098-A1 Inhibitors of protein kinases MAP3K20, MAP3K1, MAP3K19 MAP3K14 28/4885CRBN 1527/4885GLA 2043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.